Terns Pharmaceuticals (TERN) Stock
Biotech company developing treatments for liver and immune diseases. Here's the price, business snapshot, and what's worth knowing about Terns Pharmaceuticals in September 2026.
Terns Pharmaceuticals Inc (TERN) is a clinical‑stage biopharmaceutical company focused on developing small‑molecule therapies for serious diseases, with an emphasis on liver and immune‑related conditions. With a market capitalisation of approximately $710.6m, Terns is primarily valued on its pipeline prospects and upcoming clinical milestones rather than steady revenue. Investors typically watch clinical trial readouts, regulatory interactions and potential partnerships or licensing deals as catalysts. Biotech equities like TERN can be volatile: clinical setbacks, regulatory delays or financing needs can significantly affect the share price. This summary is for general educational purposes only and is not personalised investment advice. Shares may be suitable for investors comfortable with high risk, a long time horizon and the possibility of capital loss; consult a qualified financial adviser before making investment decisions.
Terns Pharmaceuticals (TERN) Stock Forecast
Analyst price target, next 12 months
$53.56
+1.1% vs today's $52.97
Price range over the last 12 months
Close to its 12-month high
Analysts covering Terns Pharmaceuticals have a consensus 12-month target of $53.56, above the current price of $52.97.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Terns Pharmaceuticals stock with a target price of $53.56, indicating potential growth.
Financial Health
Terns Pharmaceuticals is showing solid financial performance with healthy cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory interactions can shift investor expectations; these milestones often drive short‑term volatility and longer‑term value.
Scientific Focus
A small‑molecule approach targets liver and immune conditions, which could offer advantages in oral dosing — though clinical proof is required.
Market & Risks
Valuation reflects pipeline potential and a $710m market cap; investors should weigh funding needs, regulatory risk and the speculative nature of biotech.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
